Pharmaceutical Companies in France

Nicox is an international ophthalmic R&D company, based in Valbonne, France, dedicated to developing innovative therapeutics to help maintain vision and improve ocular health.

We focus on addressing significant unmet needs in glaucoma and ocular allergic conjunctivitis, with a leading program, NCX 470, successfully completing Phase 3 clinical development in the U.S. and China. Our portfolio also includes NCX 1728, a candidate under preclinical evaluation for retinal conditions.

Nicox leverages its proprietary nitric oxide donation research platform and strategic collaborations to advance its pipeline. We are proud to offer commercially available products, VYZULTA® for glaucoma and ZERVIATE® for ocular allergic conjunctivitis, with ZERVIATE also approved for use in China.

InFlectis BioScience is a private clinical stage company aiming at targeting and modulating interactions between proteins involved in key human pathophysiological processes. The company is developing small molecule drugs that specifically target the Integrated Stress Response (ISR). Exploiting the ISR’s natural defense offers tremendous potential for the development of a new class of therapies. Led by InFlectis, this area of research is rapidly advancing, resulting in new treatments under development for a variety of disease affecting the central nervous system (CNS), peripheral nervous system (PNS) and inflammation.

Aqemia is a pharmatech company using quantum physics and artificial intelligence to transform the drug discovery process. With a unique proprietary technology that preclude the use of experimental data, our pipeline scales the drug discovery process at an unprecedented pace, generating an exhaustive number of new drug candidates. We are hiring! Check our career website: https://jobs.lever.co/aqemia.com Blog Posts on: https://medium.com/aqemia

Biocellvia is a french company developing Intelligent Image Analysis solutions for pharmaceutical industry (Big Pharma, Biotechs, CRO) and academic communities involved in R&D. We have developed digital image analysis solutions, that enable to evaluate fully-automatically the level of efficacy of your lead molecules thanks to histological slides (in vitro, ex vivo, biopsies) in various pathologies such as: - Gastrointestinal (NASH, Liver fibrosis) - Respiratory (IPF, COPD, PAH) We provide image analysis as a service. Our technology evaluates your molecules with more accuracy, more reliability, more rapidity and less variability than traditional scoring methods. A full study (about 200 images) is performed in only a couple of days. http://biocellvia.com http://linkedin.com/company/biocellvia

New ideas, new innovations, new ways of thinking for the medical device industry. We are a pharmaceutical company specialized in the discovery, clinical development, production and commercialization of innovative products in the field of regenerative medicine. At Bioxis Pharmaceuticals, we contribute to transform science into groundbreaking medical device that meet doctors need to improve the health and well-being of their patients in the field of dermatology and aesthetic medicine.

To contact us : contact@calixar.com CALIXAR, is a biotech company specialized in the functional and native isolation of complex membrane therapeutic targets and antigens. We develop and implement chemistry and biochemistry tools to isolate in solution - with the highest purity levels - full-length membrane proteins, while keeping their structural and functional integrity. Our approach represents the opportunity for pharmaceutical companies to start and work with high quality targets or antigens before developing antibodies, formulating vaccines and/or discovering a primary lead through Structure Based Drug Design or High Throughput Screening assays. As membrane proteins represent more than 60% of pharmaceutical drug targets, to keep their native conformation during the extraction from membrane cells and solubilization is crucial. Our technological platform preserves the original structure of membrane proteins such as GPCRs, Ion channels, Transporters, Viral targets, etc.) or others native receptors acting as drug targets or antigens. As a result, this most accurate targeting helps biotechs, academic teams, pharmaceutical industries to develop highly potential drugs, bio drugs and vaccines and consequently saves significant time and money in further clinical stages. By using original chemistry and specific approaches designed on demand, we develop new tools and protocols for the identification, expression, extraction, purification and crystallization of these membrane proteins/antigens from cells or from endogenous materials (virus, bacteria, primary cells, organs, etc.). For SBDD/FBDD approaches, we carry out crystallization tests and structure determination of these native targets starting from their full-length and functional version without any point mutations or deletions. CALIXAR sets up specific R&D programs with its customers using classical and flexible business model: Fee for service, Risk sharing, Exclusivity option and Licensing out.

Datacapt provides a global, easy-to-use, flexible, and powerful electronic data capture platform (EDC) for on-site, hybrid, or decentralized Clinical Trials. We allow Sponsors, CROs, and Subjects to work together in a simple way with a huge engagement. Our Platform brings simplicity, efficiency, and quality to the collection of clinical data. Datacapt is making the promise to simplify and accelerate clinical tests with innovative solutions. Simplify the management of your trial with the Datacapt platform. Developed with specialists and experts, our platform is flexible and adapted to your studies. We offer a modular platform with everything in one place to design and manage all your trials (EDC, eCRF, ePRO/eCOA/eDiary, eConsent, eConsult, and Data Analysis…). - Significantly reduced time spent on study setup and management (Simple and flexible eCRF, ePRO, eConsent creation) - Real-time monitoring - Allows reducing manual tasks, data retranscription, and zero time spent on data export - Fast and easy implementation - Secure and 100% Compliant

Fab’entech is a privately owned biopharmaceutical SME based in Lyon (France) and created in 2009, which develops immunotherapies to address situations of emergency. In an environment where the globalization of trade accelerates the spread of epidemics and where the geopolitical context increases the risk of bioterrorist attacks, nations should be prepared to address various situations of public health & medical emergency. However, there is generally no real therapeutic option to fight acute symptoms arising from these neglected indications. Based on its horse F(ab’)2 platform, a fully-derisked technology in-licensed from Sanofi Pasteur, Fab’entech aims to provide therapeutic solutions in the fields of biodefense, drug intoxication and infectious disease. After having developed Fabenflu®, a product indicated for the treatment of avian influenza (H5N1) in human, Fab’entech is currently focusing on 3 products: a biodefense antidote developed in collaboration with the French army, a treatment for drug intoxication developed in a confidential indication, and an Ebola therapy developed with the support of the European Commission after having been identified by the WHO as the unique therapeutic solution in Europe in 2014.

Livmed's is a software platform that provides home medicine delivery services for fellow citizens and healthcare players.

OSE Immunotherapeutics is an integrated biotech company focused on developing first-in-class assets targeting cancer and inflammatory diseases. A current well-balanced first-in-class clinical pipeline including: • Tedopi® (T-cell specific immunotherapy): Company’s most advanced product; positive results for Ph 3 in NSCLC in secondary resistance after CKI failure. Other sponsored combo Ph 2 trials in solid tumors ongoing. • OSE-279 (anti-PD1) advanced preclinical stage • OSE-127 (humanized mAb antagonist of IL-7R); ongoing Ph 2 in Ulcerative Colitis; ongoing preclinical research in leukemia • VEL-101/FR104 (anti-CD28 mAb) developed in partnership with Veloxis in transplantation; ongoing Ph 1/2 in renal transplant (sponsor Nantes University Hospital); Ph 1 ongoing in the US (sponsor Veloxis). • BI 765063 (anti-SIRPα mAb on CD47/SIRPα pathway) developed in partnership with Boehringer Ingelheim in advanced solid tumors; positive Ph 1 dose escalation results in mono and in combo, in particular with anti-PD-1 antibody ezabenlimab; BI sponsored international Ph 1b clinical trial ongoing in combo with ezabenlimab alone or with other drugs in recurrent/metastatic HNSCC and HCC. OSE Immunotherapeutics expects to generate further significant value from its two proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapeutics: • BiCKI® platform focused on immuno-oncology (IO) is a bispecific fusion protein platform built on the key backbone component of anti-PD1 combined with a new immunotherapy target to increase anti-tumor efficacy. Most advanced BiCKI® candidate is targeting anti-PD1xIL-7. • Myeloid platform focused on optimizing the therapeutic potential of myeloid cells in IO & immuno-inflammation (I&I). OSE-230 (ChemR23 agonist mAb), most advanced candidate generated by the platform, with the potential to resolve chronic inflammation.

Kayentis, a global provider of eCOA (electronic Clinical Outcome Assessment) and Decentralized Clinical Trial solutions (DCTs), helps pharma, biotech and CROs bring simplicity, efficiency and quality to the collection of clinical trial data from both patients and sites. Since 2005, Kayentis has been active in clinical development, with a strong specialization in eCOA solutions for phases I-IV across a broad range of therapeutic areas. Over the years, it has developed a full range of services and has enlarged its portfolio beyond eCOA solutions to support the new normal of decentralized and hybrid trials. The company has conducted digital data collection for over 300 clinical trials in 90 countries (100,000 patients), employing 120 languages. It has offices in the US (Boston), France (Grenoble) and Japan (Tokyo), and currently employs 185 staff.

Excelya is an independent partner that serves Biotech, Pharma, and Medical Device organizations with a comprehensive range of Full-service CRO, FSP, and Resourcing solutions guided by compassion, care, and excellence.  Founded in 2014 and headquartered in Paris, France, and operating in 28 countries across Europe, USA and India, Excelya has a global team of 900+ experts who understand the critical needs of clients to provide bespoke and robust trial solutions across a broad spectrum of therapeutic areas, with speciality focus on Oncology & Hematology, Rare Disease & Pediatrics, Infectious Disease, Inflammation & Immunotherapy, Pain Treatment & CNS, and Late Phase & RWE.

Guerbet is a global leader in medical imaging, dedicated to improving patient care through innovation. With nearly a century of expertise, the company offers a comprehensive portfolio of pharmaceutical products, medical devices, and AI-driven solutions for diagnostic and interventional imaging. Guerbet invests 9% of its annual revenue in research and development, with dedicated innovation centers in France and the United States.

PHARMAnetwork PHARMAnetwork is a company specialized in publishing for the pharmaceutical industry. PHARMAnetwork has developed publications for CMO, CDMO and professionals working in the life sciences. PHARMAnetwork designs specialized studies for pharmaceutical companies, contract service providers and investment firms. http://www.pharmanetwork.com PHARMAnetwork magazine covers, every aspect of pharmaceutical value chain, the change and developments in the intersection between pharmaceutical industry and outsourcing industry. We perform interviews and write articles whose thematic strategies, organizations, mergers and acquisitions, regulatory, innovation in the pharmaceutical development and contract manufacturing. https://www.pharmanetwork.digital

SEQENS is a worldwide leader in pharmaceutical solutions and specialty ingredients. The group generates a revenue of 1.1 MM€ and operates 16 manufacturing plants and 9 R&D centers in Europe, North America and Asia. 3,300 employees contribute to the success of SEQENS, among which 350 scientists, engineers and experts who develop tailor-made solutions for our customers. SEQENS is an integrated player offering a broad portfolio of active ingredients, pharmaceutical intermediates and specialty ingredients. We develop and industrialize the most demanding molecules, and rely on our ability to innovate, develop and implement the best available technologies.

1001Pharmacies is a French drugstore that sells personal health and well-being products online.

Emulseo is a startup company dedicated to the design and production of high-quality formulations for microfluidic applications. Our service is based upon long-term know-how and expertise in the field of microfluidics for pharmaceutical, biotech and chemical industry. Check out our website to discover our choice of fluorinated surfactants, fluorinated oils, surface treatments and many more products to come! Whatever your application, we have a dedicated team of scientists focused on working closely with you to provide products and custom-made solutions of the highest quality and guide you through your projects.

Vaxxel develops novel and proprietary live-attenuated vaccines candidate against bronchiolitis and pneumonia and in particular against human Metnapneumovirus and against human Respiratory Virus. Vaxxel is a spin off fom Virpath, the virology and human pathology Laboratory of the University Claude Bernard in Lyon (UCBL), France, and has been founded by Dr. Manuel Rosa-Calatrava Co-Director of Virpath (Lyon), Pr. Guy Boivin of the University of Laval (Quebec), by Denis Cavert, President of Vaxxel.

Fort d'une expertise reconnue dans le domaine des compteurs de particules, Aerometrik propose une gamme d’équipements de mesure à la vente et à la location. Ces solutions intègrent des compteurs de particules portables et fixes CLIMET, des biocollecteurs portables et fixes CLIMET, des générateurs & photomètres ATI, des anémomètres et balomètres TSI ainsi que les services de métrologie associés permettant d'accompagner ses clients dans l’approche maîtrisée de la contamination de l'air des zones de production critiques dans les industries de l’ultra-propreté. Chaque environnement nécessite une stratégie et des moyens définis pour garantir l’absence de risque de contamination microbiologique au regard des process et de la nature des produits fabriqués. Au travers d’une expérience et d’une méthodologie éprouvée, nous vous accompagnons dans la mise en oeuvre de monitoring particulaire et microbiologique pour le contrôle périodique ou en temps réel de votre environnement en développant des solutions sur mesure adaptées à vos contraintes et en garantissant une grande fiabilité des mesures réalisées.

Ceva Santé Animale (Ceva) is the 5th global animal health company, led by experienced veterinarians, whose mission is to provide innovative health solutions for all animals to ensure the highest level of care and well-being. Our portfolio includes preventive medicine such as vaccines and animal welfare products, pharmaceutical solutions for farm and companion animals, as well as equipment and services to provide the best experience for our customers. With more than 7,000 employees located in 47 countries, Ceva strives daily to bring to life its vision as a One Health company: “Together, beyond animal health”. Our 21 R&D centers and 33 production sites worldwide attest to our commitment to research and the development of increasingly innovative solutions.  2023 turnover: €1.62 billion. https://www.ceva.com

Laboratoire responsable et engagé, notre ambition est d’être un leader européen indépendant dans le domaine des médicaments essentiels. Notre mission depuis 40 ans : agir ensemble, chaque jour, pour garantir aux patients un accès fiable à des médicaments essentiels. Nous développons, produisons et commercialisons des médicaments génériques injectables à destination des hôpitaux et des cliniques en France et dans plus de 75 pays sur les 5 continents. A travers trois sites de production en France et en Allemagne, nous sommes spécialisés dans les domaines des antibiotiques, anesthésiques et antalgiques injectables génériques. Laboratoire responsable, doté d’une vision long terme, nous avons décidé d’investir plus de 40M€ sur 4 ans (2022-2025) pour moderniser, sécuriser et accroitre les capacités de production de nos sites de Luitré-Dompierre (Bretagne, France) et de Trittau (Allemagne). ETI familiale française de 600 collaborateurs, nous sommes fiers d’avoir su garder une culture d’entreprise avec des valeurs fortes comme : la simplicité - l’esprit d’entreprendre - le travail en équipe - la performance et la responsabilité. L’engagement des équipes, qui ont toujours fait preuve d’initiatives, d’expertise, d’agilité, de cohésion et de ténacité nous permet d’être aujourd’hui le dernier laboratoire à produire sur le sol français l’un des plus larges portefeuilles d’antibiotiques injectables. Rejoindre le Groupe Panpharma c’est se donner l’opportunité de travailler dans un secteur ouvert à l’international, dynamique et stimulant. Les métiers de Panpharma sont riches et variés et nous nous employons au quotidien à faire grandir et développer les compétences de chacun de nos collaborateurs. Vous avez envie de sens au travail et de contribuer à la réalisation de la mission de Panpharma ? Retrouvez l’ensemble de nos offres d’emploi sur notre site internet ou faites-nous parvenir votre candidature sur l’adresse job@panpharma.fr